PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 33730336-1 2021 INTRODUCTION: STELLA-LONG TERM is a post-marketing surveillance study evaluating the safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus. ipragliflozin 113-126 developmental pluripotency associated 3 Homo sapiens 14-20 33957565-8 2021 We found that intragastric phlorizin did not display any effects, but ipragliflozin, an orally active and selective SGLT2 inhibitor improved the gastrointestinal changes in the LPS model. ipragliflozin 70-83 solute carrier family 5 member 2 Rattus norvegicus 116-121 34018149-0 2021 Correction to: Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM. ipragliflozin 43-56 developmental pluripotency associated 3 Homo sapiens 148-154 33611885-0 2021 Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/SIRT1 Pathway. ipragliflozin 0-13 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 18-23 33827996-1 2021 The STELLA-LONG TERM prospective post-marketing surveillance study assessed ipragliflozin in Japanese patients with type 2 diabetes mellitus (T2DM). ipragliflozin 76-89 developmental pluripotency associated 3 Homo sapiens 4-10 33611885-0 2021 Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/SIRT1 Pathway. ipragliflozin 0-13 sirtuin 1 Mus musculus 153-158 33611885-3 2021 Therefore, we investigated the effect of ipragliflozin (a selective SGLT2 inhibitor) on energy metabolism. ipragliflozin 41-54 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 68-73 33611885-8 2021 In the ipragliflozin treatment group, uncoupling protein 1 (Ucp1) and other thermogenesis-related genes were significantly upregulated in the visceral and subcutaneous adipose tissue, and fatty acid oxidation was increased in the brown adipose tissue. ipragliflozin 7-20 uncoupling protein 1 (mitochondrial, proton carrier) Mus musculus 38-58 33611885-8 2021 In the ipragliflozin treatment group, uncoupling protein 1 (Ucp1) and other thermogenesis-related genes were significantly upregulated in the visceral and subcutaneous adipose tissue, and fatty acid oxidation was increased in the brown adipose tissue. ipragliflozin 7-20 uncoupling protein 1 (mitochondrial, proton carrier) Mus musculus 60-64 33611885-10 2021 Conclusion: SGLT2 inhibition by ipragliflozin showed beneficial metabolic effects in 129S6/Sv mice with HFD-induced obesity that mimics prediabetic conditions. ipragliflozin 32-45 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 12-17 33069809-4 2020 RESULTS: The treatment with ipragliflozin, but not insulin, suppressed megalin O-GlcNAcylation and accelerated its internalization, resulting in reduction in proximal tubular reabsorption of the highly filtered plasma proteins such as albumin and neutrophil gelatinase-associated lipocalin. ipragliflozin 28-41 low density lipoprotein receptor-related protein 2 Mus musculus 71-78 33012212-0 2021 Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM). ipragliflozin 62-75 developmental pluripotency associated 3 Homo sapiens 189-195 32623839-7 2021 However, TRACP-5b levels increased in patients treated with ipragliflozin compared to patients treated with metformin (median 11.94 % vs. -10.30 %, P < 0.0001), indicating that ipragliflozin can promote bone resorption. ipragliflozin 60-73 acid phosphatase 5, tartrate resistant Homo sapiens 9-17 32623839-7 2021 However, TRACP-5b levels increased in patients treated with ipragliflozin compared to patients treated with metformin (median 11.94 % vs. -10.30 %, P < 0.0001), indicating that ipragliflozin can promote bone resorption. ipragliflozin 177-190 acid phosphatase 5, tartrate resistant Homo sapiens 9-17 32623839-9 2021 However, ipragliflozin combination increased the levels of TRACP-5b. ipragliflozin 9-22 acid phosphatase 5, tartrate resistant Homo sapiens 59-67 32623839-10 2021 A long-term study is needed to further understand the effects of this TRACP-5b increase caused by ipragliflozin. ipragliflozin 98-111 acid phosphatase 5, tartrate resistant Homo sapiens 70-78 33069809-4 2020 RESULTS: The treatment with ipragliflozin, but not insulin, suppressed megalin O-GlcNAcylation and accelerated its internalization, resulting in reduction in proximal tubular reabsorption of the highly filtered plasma proteins such as albumin and neutrophil gelatinase-associated lipocalin. ipragliflozin 28-41 lipocalin 2 Mus musculus 247-289 32149469-10 2020 In cases with low eGFR (eGFR>=30 <60), ipragliflozin has the possibility of increasing eGFR in cases with low eGFR and exerting a renoprotective effect. ipragliflozin 39-52 epidermal growth factor receptor Homo sapiens 24-28 33786273-1 2021 STELLA-LONG TERM, a 3-year post-marketing surveillance study, evaluated the safety and effectiveness of the sodium-glucose cotransporter 2 inhibitor ipragliflozin in Japanese type 2 diabetes mellitus (T2DM) patients. ipragliflozin 149-162 developmental pluripotency associated 3 Homo sapiens 0-6 33786273-1 2021 STELLA-LONG TERM, a 3-year post-marketing surveillance study, evaluated the safety and effectiveness of the sodium-glucose cotransporter 2 inhibitor ipragliflozin in Japanese type 2 diabetes mellitus (T2DM) patients. ipragliflozin 149-162 solute carrier family 5 member 2 Homo sapiens 108-138 33786274-9 2021 These results suggest that the ipragliflozin-induced increase in hematocrit which is affected by the baseline hematocrit level is attributable to the responsiveness to, but not to the production of, erythropoietin. ipragliflozin 31-44 erythropoietin Homo sapiens 199-213 32100949-0 2020 Long-term efficacy of the sodium-glucose cotransporter 2 inhibitor ipragliflozin in a case of type A insulin resistance syndrome. ipragliflozin 67-80 solute carrier family 5 member 2 Homo sapiens 26-56 32149469-10 2020 In cases with low eGFR (eGFR>=30 <60), ipragliflozin has the possibility of increasing eGFR in cases with low eGFR and exerting a renoprotective effect. ipragliflozin 39-52 epidermal growth factor receptor Homo sapiens 24-28 32100949-4 2020 We report a case of type A IR syndrome with an in-frame INSR heterozygous deletion (DeltaLeu999) that was treated with a combination of conventional therapy and ipragliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor. ipragliflozin 161-174 insulin receptor Homo sapiens 56-60 32100949-4 2020 We report a case of type A IR syndrome with an in-frame INSR heterozygous deletion (DeltaLeu999) that was treated with a combination of conventional therapy and ipragliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor. ipragliflozin 161-174 solute carrier family 5 member 2 Homo sapiens 210-215 33015603-2 2020 Objective: We aimed to explore whether SGLT2 inhibitor ipragliflozin has a direct reno-protective effect on non-diabetic chronic kidney disease (CKD) in mice. ipragliflozin 55-68 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 39-44 32149469-9 2020 CONCLUSIONS: Ipragliflozin lowers eGFR and corrects hyperfiltration in cases with high eGFR (eGFR >=60). ipragliflozin 13-26 epidermal growth factor receptor Homo sapiens 34-38 32149469-9 2020 CONCLUSIONS: Ipragliflozin lowers eGFR and corrects hyperfiltration in cases with high eGFR (eGFR >=60). ipragliflozin 13-26 epidermal growth factor receptor Homo sapiens 87-91 32149469-9 2020 CONCLUSIONS: Ipragliflozin lowers eGFR and corrects hyperfiltration in cases with high eGFR (eGFR >=60). ipragliflozin 13-26 epidermal growth factor receptor Homo sapiens 87-91 32149469-10 2020 In cases with low eGFR (eGFR>=30 <60), ipragliflozin has the possibility of increasing eGFR in cases with low eGFR and exerting a renoprotective effect. ipragliflozin 39-52 epidermal growth factor receptor Homo sapiens 18-22 32149469-10 2020 In cases with low eGFR (eGFR>=30 <60), ipragliflozin has the possibility of increasing eGFR in cases with low eGFR and exerting a renoprotective effect. ipragliflozin 39-52 epidermal growth factor receptor Homo sapiens 24-36 32183468-0 2020 Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin. ipragliflozin 136-149 sodium/glucose cotransporter 2 Cricetulus griseus 61-91 32821334-4 2020 The SGLT2 inhibitor ipragliflozin has reportedly improved liver steatosis in animal models and clinical studies. ipragliflozin 20-33 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 4-9 32821334-11 2020 Ipragliflozin had no appreciable effects on hepatic oxidative stress-related gene expression levels or macrophage infiltration, but significantly reduced hepatic interleukin-1beta (IL-1beta) mRNA expression levels. ipragliflozin 0-13 interleukin 1 beta Mus musculus 162-179 32821334-11 2020 Ipragliflozin had no appreciable effects on hepatic oxidative stress-related gene expression levels or macrophage infiltration, but significantly reduced hepatic interleukin-1beta (IL-1beta) mRNA expression levels. ipragliflozin 0-13 interleukin 1 alpha Mus musculus 181-189 32821334-12 2020 Ipragliflozin increased both the mRNA and protein expression levels of sirtuin 1 (SIRT1) in the liver. ipragliflozin 0-13 sirtuin 1 Mus musculus 71-80 32821334-12 2020 Ipragliflozin increased both the mRNA and protein expression levels of sirtuin 1 (SIRT1) in the liver. ipragliflozin 0-13 sirtuin 1 Mus musculus 82-87 32821334-13 2020 The hepatic mRNA levels of peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1alpha), peroxisome proliferator-activated receptor alpha (PPARalpha), and fibroblast growth factor-21 (FGF21) were also significantly higher in ipragliflozin-treated ob/ob mice than in untreated ob/ob mice. ipragliflozin 245-258 peroxisome proliferative activated receptor, gamma, coactivator 1 alpha Mus musculus 27-94 32821334-14 2020 CONCLUSION: Our study suggests that the liver steatosis-ameliorating effects of ipragliflozin in ob/ob mice may be mediated partly by hepatic SIRT1 signaling, possibly through the PGC-1alpha/PPARalpha-FGF21 pathway. ipragliflozin 80-93 sirtuin 1 Mus musculus 142-147 32821334-14 2020 CONCLUSION: Our study suggests that the liver steatosis-ameliorating effects of ipragliflozin in ob/ob mice may be mediated partly by hepatic SIRT1 signaling, possibly through the PGC-1alpha/PPARalpha-FGF21 pathway. ipragliflozin 80-93 peroxisome proliferative activated receptor, gamma, coactivator 1 alpha Mus musculus 180-190 32821334-14 2020 CONCLUSION: Our study suggests that the liver steatosis-ameliorating effects of ipragliflozin in ob/ob mice may be mediated partly by hepatic SIRT1 signaling, possibly through the PGC-1alpha/PPARalpha-FGF21 pathway. ipragliflozin 80-93 peroxisome proliferator activated receptor alpha Mus musculus 191-200 32821334-14 2020 CONCLUSION: Our study suggests that the liver steatosis-ameliorating effects of ipragliflozin in ob/ob mice may be mediated partly by hepatic SIRT1 signaling, possibly through the PGC-1alpha/PPARalpha-FGF21 pathway. ipragliflozin 80-93 fibroblast growth factor 21 Mus musculus 201-206 31743569-1 2020 INTRODUCTION: The aim of the present study was to assess the long-term (52-week) efficacy and safety of ipragliflozin in insulin-treated Japanese patients with type 1 diabetes mellitus and inadequate glycemic control. ipragliflozin 104-117 insulin Homo sapiens 121-128 31743569-11 2020 CONCLUSIONS: The efficacy and safety of 50 mg, once-daily ipragliflozin in insulin-treated type 1 diabetes mellitus patients were confirmed in this long-term, open-label extension study. ipragliflozin 58-71 insulin Homo sapiens 75-82 32166619-0 2020 Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus. ipragliflozin 68-81 solute carrier family 5 member 2 Homo sapiens 95-125 32166619-0 2020 Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus. ipragliflozin 68-81 solute carrier family 5 member 2 Homo sapiens 127-132 32183468-7 2020 In conclusion, selective and competitive SGLT2 inhibition of DWP16001 could potentiate the efficacy of DWP16001 in coordination with the higher kidney distribution and retained SGLT2 inhibition of DWP16001 relative to dapagliflozin and ipragliflozin. ipragliflozin 236-249 sodium/glucose cotransporter 2 Cricetulus griseus 41-46 32134370-7 2020 Canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, luseogliflozin, and tofogliflozin are known to be SGLT-2 inhibitors. ipragliflozin 45-58 solute carrier family 5 member 2 Homo sapiens 110-116 31776304-0 2020 SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation. ipragliflozin 16-29 solute carrier family 5 member 2 Homo sapiens 0-5 31776304-3 2020 In the present study, we examined the anti-cancer effect of the sodium-glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin using a breast cancer model. ipragliflozin 113-126 solute carrier family 5 member 2 Homo sapiens 64-94 31776304-3 2020 In the present study, we examined the anti-cancer effect of the sodium-glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin using a breast cancer model. ipragliflozin 113-126 solute carrier family 5 member 2 Homo sapiens 96-101 31776304-7 2020 Because the effect of ipragliflozin against breast cancer cells was completely canceled by knocking down SGLT2, ipragliflozin could act via inhibiting SGLT2. ipragliflozin 22-35 solute carrier family 5 member 2 Homo sapiens 105-110 31776304-7 2020 Because the effect of ipragliflozin against breast cancer cells was completely canceled by knocking down SGLT2, ipragliflozin could act via inhibiting SGLT2. ipragliflozin 112-125 solute carrier family 5 member 2 Homo sapiens 105-110 31776304-7 2020 Because the effect of ipragliflozin against breast cancer cells was completely canceled by knocking down SGLT2, ipragliflozin could act via inhibiting SGLT2. ipragliflozin 112-125 solute carrier family 5 member 2 Homo sapiens 151-156 31776304-10 2020 In addition, glucose-free medium and knockdown of SGLT2 by siRNA suppressed the glucose-induced whole-cell current of MCF-7 cells, suggesting that ipragliflozin inhibits sodium and glucose cotransport through SGLT2. ipragliflozin 147-160 solute carrier family 5 member 2 Homo sapiens 50-55 31776304-10 2020 In addition, glucose-free medium and knockdown of SGLT2 by siRNA suppressed the glucose-induced whole-cell current of MCF-7 cells, suggesting that ipragliflozin inhibits sodium and glucose cotransport through SGLT2. ipragliflozin 147-160 solute carrier family 5 member 2 Homo sapiens 209-214 31776304-12 2020 These findings suggest that the SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation via membrane hyperpolarization and mitochondrial membrane instability. ipragliflozin 48-61 solute carrier family 5 member 2 Homo sapiens 32-37 31955626-0 2020 Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice. ipragliflozin 39-52 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 23-28 31955626-4 2020 Here, we investigated the therapeutic effects of the SGLT2 selective inhibitor ipragliflozin alone and in combination with metformin on NASH in high fat and cholesterol diet-fed KK/Ay type 2 diabetic mice.Results: This diabetic model had hyperglycemia, insulin resistance, and obesity, and also exhibited steatosis, inflammation, and fibrosis in the liver, pathological features resembling those in human NASH. ipragliflozin 79-92 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 53-58 31955626-5 2020 Four-week repeated administration of ipragliflozin significantly improved not only hyperglycemia, insulin resistance, and obesity but also hyperlipidemia and NASH-associated symptoms including hepatic steatosis and fibrosis. ipragliflozin 37-50 insulin Homo sapiens 98-105 31955626-8 2020 In addition, combination treatment with ipragliflozin and metformin additively improved these symptoms.Conclusions: These results demonstrate that the SGLT2 selective inhibitor ipragliflozin improves not only hyperglycemia but also NASH in type 2 diabetic mice, suggesting that treatment with ipragliflozin alone and in combination with metformin may be effective for treating type 2 diabetes with NASH. ipragliflozin 40-53 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 151-156 31955626-8 2020 In addition, combination treatment with ipragliflozin and metformin additively improved these symptoms.Conclusions: These results demonstrate that the SGLT2 selective inhibitor ipragliflozin improves not only hyperglycemia but also NASH in type 2 diabetic mice, suggesting that treatment with ipragliflozin alone and in combination with metformin may be effective for treating type 2 diabetes with NASH. ipragliflozin 177-190 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 151-156 31955626-8 2020 In addition, combination treatment with ipragliflozin and metformin additively improved these symptoms.Conclusions: These results demonstrate that the SGLT2 selective inhibitor ipragliflozin improves not only hyperglycemia but also NASH in type 2 diabetic mice, suggesting that treatment with ipragliflozin alone and in combination with metformin may be effective for treating type 2 diabetes with NASH. ipragliflozin 177-190 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 151-156 32115517-1 2020 Objective To examine the add-on effects, compared to the existing antidiabetes treatment, of the sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and the risk factors of cardiovascular disease (CVD) and chronic kidney disease (CKD) in patients with inadequately controlled type 2 diabetes. ipragliflozin 138-151 solute carrier family 5 member 2 Homo sapiens 97-127 31173455-12 2019 CONCLUSIONS: Daily ipragliflozin 50 mg in combination with insulin significantly reduced HbA1c, daily insulin dose and body weight versus placebo in people with T1DM. ipragliflozin 19-32 insulin Homo sapiens 102-109 31994353-2 2020 The glycosuric effect of the SGLT2 inhibitor ipragliflozin is linked to a diuretic and natriuretic effect that activates compensatory increases in fluid and food intake to stabilize body fluid volume (BFV). ipragliflozin 45-58 solute carrier family 5 member 2 Rattus norvegicus 29-34 31994353-8 2020 Urine vasopressin in ipragliflozin-treated rats was negatively and positively associated with fluid balance and TcH2O, respectively. ipragliflozin 21-34 arginine vasopressin Rattus norvegicus 6-17 31994353-9 2020 Ipragliflozin increased the renal membrane protein expression of SGLT2, aquaporin (AQP) 2 phosphorylated at Ser269 and vasopressin V2 receptor. ipragliflozin 0-13 solute carrier family 5 member 2 Rattus norvegicus 65-70 31994353-9 2020 Ipragliflozin increased the renal membrane protein expression of SGLT2, aquaporin (AQP) 2 phosphorylated at Ser269 and vasopressin V2 receptor. ipragliflozin 0-13 arginine vasopressin receptor 2 Rattus norvegicus 119-142 31994353-11 2020 In conclusion, the SGLT2 inhibitor ipragliflozin induced a sustained glucosuria, diuresis, and natriuresis, with compensatory increases in fluid intake and vasopressin-induced TcH2O in proportion to the reduced fluid balance to maintain BFV. ipragliflozin 35-48 solute carrier family 5 member 2 Rattus norvegicus 19-24 31994353-11 2020 In conclusion, the SGLT2 inhibitor ipragliflozin induced a sustained glucosuria, diuresis, and natriuresis, with compensatory increases in fluid intake and vasopressin-induced TcH2O in proportion to the reduced fluid balance to maintain BFV. ipragliflozin 35-48 arginine vasopressin Rattus norvegicus 156-167 31237132-1 2019 We aimed to identify the clinical variables associated with a better glucose-lowering response to the sodium glucose cotransporter 2 inhibitor ipragliflozin in people with type 2 diabetes mellitus (T2DM). ipragliflozin 143-156 solute carrier family 5 member 2 Homo sapiens 102-132 31768494-2 2019 Although clinical data suggest that SGLT2is (empagliflozin, dapagliflozin, ertugliflozin, canagliflozin, ipragliflozin) are safe and protect against renal and cardiovascular events, very little attention has been dedicated to the effects of these compounds on different electrolytes. ipragliflozin 105-118 solute carrier family 5 member 2 Homo sapiens 36-41 31782258-0 2019 SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model. ipragliflozin 16-29 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 0-5 31782258-11 2019 These findings indicate that the SGLT2-selective inhibitor ipragliflozin improves hyperglycemia as well as NASH in type 2 diabetic mice. ipragliflozin 59-72 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 33-38 31888083-5 2019 We aimed to investigate the role of ELD and ER stress in the development of CKD, and evaluate the efficacy of a sodium glucose cotransporter-2 inhibitor, ipragliflozin. ipragliflozin 154-167 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 112-142 31888083-10 2019 Ipragliflozin also reduced the expression levels of GRP78 and CHOP, apoptotic cells, and interstitial fibrosis. ipragliflozin 0-13 heat shock protein 5 Mus musculus 52-57 31888083-10 2019 Ipragliflozin also reduced the expression levels of GRP78 and CHOP, apoptotic cells, and interstitial fibrosis. ipragliflozin 0-13 DNA-damage inducible transcript 3 Mus musculus 62-66 31552641-0 2019 Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy. ipragliflozin 43-56 insulin Homo sapiens 70-77 31552641-0 2019 Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy. ipragliflozin 43-56 insulin Homo sapiens 135-142 31552641-2 2019 In this study, therefore, we examined insulin dose reduction by ipragliflozin add-on therapy in Japanese patients with type 2 diabetes mellitus treated with long-acting basal insulin. ipragliflozin 64-77 insulin Homo sapiens 38-45 31552641-15 2019 Conclusions Once-daily 50-mg ipragliflozin enabled a 30% dose reduction of insulin by Week 24 compared with baseline. ipragliflozin 29-42 insulin Homo sapiens 75-82 31606880-1 2019 INTRODUCTION: Ipragliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor approved for the treatment of type 2 diabetes mellitus (T2DM). ipragliflozin 14-27 solute carrier family 5 member 2 Homo sapiens 43-73 31606880-1 2019 INTRODUCTION: Ipragliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor approved for the treatment of type 2 diabetes mellitus (T2DM). ipragliflozin 14-27 solute carrier family 5 member 2 Homo sapiens 75-80 31347926-1 2019 Objective: STELLA-LONG TERM is an ongoing post-marketing surveillance study examining the safety and effectiveness of ipragliflozin in real-world clinical practice in Japan. ipragliflozin 118-131 developmental pluripotency associated 3 Homo sapiens 11-17 31026084-0 2019 Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium-glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus. ipragliflozin 111-124 solute carrier family 5 member 2 Homo sapiens 138-168 30688412-9 2019 CONCLUSIONS: The present results suggest that ipragliflozin improved glycemic control and reduced bodyweight, but also reduced serum leptin levels and might thereby have increased appetite. ipragliflozin 46-59 leptin Homo sapiens 133-139 31125563-0 2019 Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy. ipragliflozin 10-23 solute carrier family 5 member 2 Rattus norvegicus 28-33 31197753-2 2019 These data revealed significant variations among patients with type 2 diabetes mellitus (T2DM), and there was a significant negative correlation between the renal threshold for glucose reabsorption and HbA1c levels following treatment with the sodium-glucose co-transporter 2 (SGLT2) inhibitor ipragliflozin. ipragliflozin 294-307 solute carrier family 5 member 2 Homo sapiens 244-275 31197753-2 2019 These data revealed significant variations among patients with type 2 diabetes mellitus (T2DM), and there was a significant negative correlation between the renal threshold for glucose reabsorption and HbA1c levels following treatment with the sodium-glucose co-transporter 2 (SGLT2) inhibitor ipragliflozin. ipragliflozin 294-307 solute carrier family 5 member 2 Homo sapiens 277-282 31125563-1 2019 AIMS: We investigated the effect of the selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin on cardiac dysfunction and histopathology in a non-diabetic rat model of cardiomyopathy. ipragliflozin 109-122 solute carrier family 5 member 2 Rattus norvegicus 50-90 31125563-1 2019 AIMS: We investigated the effect of the selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin on cardiac dysfunction and histopathology in a non-diabetic rat model of cardiomyopathy. ipragliflozin 109-122 solute carrier family 5 member 2 Rattus norvegicus 92-97 31234839-0 2019 Ipragliflozin-induced adipose expansion inhibits cuff-induced vascular remodeling in mice. ipragliflozin 0-13 WD and tetratricopeptide repeats 1 Mus musculus 22-29 30536746-0 2019 Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial. ipragliflozin 0-13 solute carrier family 5 member 2 Homo sapiens 17-47 30536746-0 2019 Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial. ipragliflozin 0-13 insulin Homo sapiens 163-170 31234839-11 2019 CONCLUSIONS: The Ipra-induced changes of abdominal PVAT will lead to a better understanding of unveiled mechanisms by which SGLT2 inhibitors prevent cardiovascular complications in T2DM, and the development of new therapeutic strategies targeting PVAT. ipragliflozin 17-21 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 124-129 30914436-8 2019 Ipragliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, lowered PKC activity in distal convoluted tubule cells and reduced KLHL3S433-P and NCC levels, whereas the thiazolidinedione pioglitazone did not, although the two agents similarly reduced in blood glucose levels. ipragliflozin 0-13 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 17-47 32743434-0 2019 Clinical response to sodium glucose co-transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma. ipragliflozin 63-76 solute carrier family 5 member 2 Homo sapiens 21-52 32743434-6 2019 Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, treatment was initiated to control blood glucose levels. ipragliflozin 0-13 solute carrier family 5 member 2 Homo sapiens 17-48 30914436-8 2019 Ipragliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, lowered PKC activity in distal convoluted tubule cells and reduced KLHL3S433-P and NCC levels, whereas the thiazolidinedione pioglitazone did not, although the two agents similarly reduced in blood glucose levels. ipragliflozin 0-13 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 49-54 30914436-8 2019 Ipragliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, lowered PKC activity in distal convoluted tubule cells and reduced KLHL3S433-P and NCC levels, whereas the thiazolidinedione pioglitazone did not, although the two agents similarly reduced in blood glucose levels. ipragliflozin 0-13 proline rich transmembrane protein 2 Homo sapiens 75-78 30914436-8 2019 Ipragliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, lowered PKC activity in distal convoluted tubule cells and reduced KLHL3S433-P and NCC levels, whereas the thiazolidinedione pioglitazone did not, although the two agents similarly reduced in blood glucose levels. ipragliflozin 0-13 kelch like family member 3 Homo sapiens 134-145 30485488-0 2019 First-dose effect of the SGLT2 inhibitor ipragliflozin on cardiovascular activity in spontaneously diabetic Torii fatty rats. ipragliflozin 41-54 solute carrier family 5 member 2 Rattus norvegicus 25-30 30937121-0 2019 Differing Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Ipragliflozin on the Decrease of Fat Mass vs. ipragliflozin 65-78 solute carrier family 5 member 2 Homo sapiens 24-54 30937121-2 2019 Background: We previously reported changes of body composition determined by dual-energy X-ray absorptiometry after treatment with ipragliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor. ipragliflozin 131-144 solute carrier family 5 member 2 Homo sapiens 148-178 30937121-2 2019 Background: We previously reported changes of body composition determined by dual-energy X-ray absorptiometry after treatment with ipragliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor. ipragliflozin 131-144 solute carrier family 5 member 2 Homo sapiens 180-185 30767112-1 2019 INTRODUCTION: The present interim report of the STELLA-LONG TERM study aimed to examine the safety and effectiveness of ipragliflozin in real-word clinical practice in Japan using data up to 12 months. ipragliflozin 120-133 developmental pluripotency associated 3 Homo sapiens 48-54 30485488-2 2019 We aimed to determine whether the first dose of the selective SGLT2 inhibitor ipragliflozin affects cardiovascular activity in non-diabetic Sprague-Dawley (SD) rats and Spontaneously Diabetic Torii (SDT) fatty rats in two studies, a urine collection study and a telemetry study. ipragliflozin 78-91 solute carrier family 5 member 2 Rattus norvegicus 62-67 30485488-11 2019 These results suggest that the first dose of the SGLT2 inhibitor ipragliflozin has little impact on cardiovascular activity despite causing glucosuria with osmotic diuresis. ipragliflozin 65-78 solute carrier family 5 member 2 Rattus norvegicus 49-54 30828082-1 2019 Ipragliflozin, a selective sodium glucose cotransporter 2 (SGLT2) inhibitor, is used for the treatment of type 2 diabetes mellitus. ipragliflozin 0-13 sodium/glucose cotransporter 2 Cricetulus griseus 27-57 31582658-5 2019 Under general anesthesia, baseline urine samples were collected from the left and right ureters for 1 h. The selective SGLT2 inhibitor ipragliflozin or vehicle was subsequently administered intravenously and post-drug urine was collected for 1 h. Baseline and post-drug blood samples were collected immediately before baseline urine collection and immediately after post-drug urine collection, respectively. ipragliflozin 135-148 solute carrier family 5 member 2 Rattus norvegicus 119-124 30828082-1 2019 Ipragliflozin, a selective sodium glucose cotransporter 2 (SGLT2) inhibitor, is used for the treatment of type 2 diabetes mellitus. ipragliflozin 0-13 sodium/glucose cotransporter 2 Cricetulus griseus 59-64 30828082-2 2019 To date, the only known in vitro pharmacological characteristic of ipragliflozin is its selectivity for SGLT2 over SGLT1, which was previously reported by our group. ipragliflozin 67-80 sodium/glucose cotransporter 2 Cricetulus griseus 104-109 30828082-4 2019 Selectivity of ipragliflozin and phlorizin for human (h) SGLT2 over hSGLT3, hSGLT4, hSGLT5, hSGLT6 and hSodium/myo-inositol (MI) cotransporter 1 (hSMIT1) was examined in Chinese hamster ovary (CHO) cells overexpressing each transporter using specific radio-ligands. ipragliflozin 15-28 solute carrier family 5 member 2 Homo sapiens 57-62 30828082-5 2019 Ipragliflozin had higher selectivity for hSGLT2 than other hSGLTs. ipragliflozin 0-13 solute carrier family 5 member 2 Homo sapiens 41-47 30828082-7 2019 Studies using CHO cells overexpressing hSGLT2 demonstrated that both ipragliflozin and phlorizin competitively inhibited SGLT2-mediated methyl-alpha-D-glucopyranoside (AMG) uptake with an inhibitory constant (Ki) of 2.28 and 20.2 nM, respectively. ipragliflozin 69-82 solute carrier family 5 member 2 Homo sapiens 39-45 30828082-7 2019 Studies using CHO cells overexpressing hSGLT2 demonstrated that both ipragliflozin and phlorizin competitively inhibited SGLT2-mediated methyl-alpha-D-glucopyranoside (AMG) uptake with an inhibitory constant (Ki) of 2.28 and 20.2 nM, respectively. ipragliflozin 69-82 sodium/glucose cotransporter 2 Cricetulus griseus 40-45 30828082-8 2019 Ipragliflozin, but not phlorizin, inhibited hSGLT2 in a wash-resistant manner, suggesting that binding of ipragliflozin to hSGLT2 was persistent. ipragliflozin 0-13 solute carrier family 5 member 2 Homo sapiens 44-50 30828082-8 2019 Ipragliflozin, but not phlorizin, inhibited hSGLT2 in a wash-resistant manner, suggesting that binding of ipragliflozin to hSGLT2 was persistent. ipragliflozin 106-119 solute carrier family 5 member 2 Homo sapiens 123-129 30828082-9 2019 These data demonstrate that ipragliflozin is a competitive inhibitor of SGLT2, has high selectivity for SGLT2 over not only SGLT1 but also other SGLT family members, and binds persistently to hSGLT2. ipragliflozin 28-41 sodium/glucose cotransporter 2 Cricetulus griseus 72-77 30828082-9 2019 These data demonstrate that ipragliflozin is a competitive inhibitor of SGLT2, has high selectivity for SGLT2 over not only SGLT1 but also other SGLT family members, and binds persistently to hSGLT2. ipragliflozin 28-41 sodium/glucose cotransporter 2 Cricetulus griseus 104-109 30828082-9 2019 These data demonstrate that ipragliflozin is a competitive inhibitor of SGLT2, has high selectivity for SGLT2 over not only SGLT1 but also other SGLT family members, and binds persistently to hSGLT2. ipragliflozin 28-41 solute carrier family 5 member 2 Homo sapiens 192-198 29893003-6 2018 Decreases in homeostatic model assessment of insulin resistance, body fat percentage and skeletal muscle mass index, and increases in free fatty acids, ketone body concentration and HDL cholesterol levels were greater in the ipragliflozin group. ipragliflozin 225-238 insulin Homo sapiens 45-52 29893003-9 2018 In conclusion, ipragliflozin had beneficial effects on fat reduction, insulin resistance and lipid metabolism, while sitagliptin had beneficial effects on beta-cell function. ipragliflozin 15-28 insulin Homo sapiens 70-77 30382157-5 2018 Ipra downregulated the gene expression of interleukin (IL)-15 (Il15) in stromal cells of Epi. ipragliflozin 0-4 interleukin 15 Mus musculus 42-61 30382157-5 2018 Ipra downregulated the gene expression of interleukin (IL)-15 (Il15) in stromal cells of Epi. ipragliflozin 0-4 interleukin 15 Mus musculus 63-67 30234161-2 2018 We investigated the efficacy of ipragliflozin (selective sodium-glucose cotransporter-2 inhibitor [SGLT2I]) for the treatment of patients with type 2 diabetes mellitus (T2DM) complicated by non-alcoholic fatty liver disease (NAFLD). ipragliflozin 32-45 solute carrier family 5 member 2 Homo sapiens 57-87 29352520-13 2018 Suppression of SGLT2 by a specific small interfering ribonucleic acid or ipragliflozin restored these GTPase levels to their normal values. ipragliflozin 73-86 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 15-20 30021338-9 2018 SIGNIFICANCE: These results indicate that the SGLT2 inhibitor, ipragliflozin, exerts antihyperglycemic actions by increasing urinary glucose excretion, and induces weight loss without a compensatory increase in food intake in type 2 diabetic mice. ipragliflozin 63-76 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 46-51 29702076-0 2018 Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice. ipragliflozin 73-86 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 57-62 29806620-0 2018 Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION). ipragliflozin 64-77 solute carrier family 5 member 2 Homo sapiens 23-53 29806620-11 2018 Interestingly, the serum adiponectin and high-density lipoprotein (HDL) cholesterol levels were significantly increased by Ipra. ipragliflozin 123-127 adiponectin, C1Q and collagen domain containing Homo sapiens 25-36 29806620-14 2018 These data suggest that Ipra decreased not only glucose level but also BMI, blood pressure and serum C-peptide, and the contributing factor for HbA1c reduction by Ipra was baseline HbA1c level. ipragliflozin 24-28 hemoglobin subunit alpha 1 Homo sapiens 144-148 29806620-14 2018 These data suggest that Ipra decreased not only glucose level but also BMI, blood pressure and serum C-peptide, and the contributing factor for HbA1c reduction by Ipra was baseline HbA1c level. ipragliflozin 163-167 hemoglobin subunit alpha 1 Homo sapiens 144-148 29806620-15 2018 Further, Ipra improved serum adiponectin and HDL cholesterol levels. ipragliflozin 9-13 adiponectin, C1Q and collagen domain containing Homo sapiens 29-40 29926400-0 2018 Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study. ipragliflozin 0-13 glucagon like peptide 1 receptor Homo sapiens 34-48 29926400-12 2018 The results from this study suggest that ipragliflozin can be recommended as a well-tolerated and effective add-on therapy to a GLP-1 receptor agonist for the treatment of T2DM. ipragliflozin 41-54 glucagon like peptide 1 receptor Homo sapiens 128-142 30800562-1 2019 Objective: To examine long-term efficacy/safety of ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, added to ongoing insulin therapy in Japanese patients with type 2 diabetes. ipragliflozin 51-64 solute carrier family 5 member 2 Homo sapiens 68-98 30800562-12 2019 Conclusions: Ipragliflozin was well tolerated, effective, and reduced bodyweight over a period of 52 weeks in patients treated with insulin with/without a DPP-4 inhibitor. ipragliflozin 13-26 insulin Homo sapiens 132-139 30800562-12 2019 Conclusions: Ipragliflozin was well tolerated, effective, and reduced bodyweight over a period of 52 weeks in patients treated with insulin with/without a DPP-4 inhibitor. ipragliflozin 13-26 dipeptidyl peptidase 4 Homo sapiens 155-160 29702076-7 2018 These results suggest that the SGLT2 inhibitor ipragliflozin prevents progression to diabetic overt nephropathy in uninephrectomized type 2 diabetic mice. ipragliflozin 47-60 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 31-36 29374293-0 2018 Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice. ipragliflozin 31-44 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 15-20 30008607-9 2018 The skin tissue-to-plasma concentration ratio of ipragliflozin was 0.45 +- 0.20 (+-SD) at 1 hr after administration and increased in a time-dependent manner to 5.82 +- 3.66 at 24 hr (p<0.05), but not in case of other SGLT2 inhibitors. ipragliflozin 49-62 solute carrier family 5 member 2 Rattus norvegicus 220-225 29110406-5 2018 We switched from thiazide diuretics to an SGLT2 inhibitor, ipragliflozin, in participants with type 2 diabetes and hypertension whose blood pressure was controlled with thiazide diuretics. ipragliflozin 59-72 solute carrier family 5 member 2 Homo sapiens 42-47 29110406-11 2018 CONCLUSIONS: Switching from thiazide diuretic to an SGLT2 inhibitor, ipragliflozin, markedly improved various metabolic parameters and body mass composition without affecting blood pressure in participants with type 2 diabetes and hypertension. ipragliflozin 69-82 solute carrier family 5 member 2 Homo sapiens 52-57 29591723-0 2018 Improvement in the proinsulin/C-peptide ratio during treatment with ipragliflozin in Japanese patients with type 2 diabetes mellitus. ipragliflozin 68-81 insulin Homo sapiens 19-29 29591723-0 2018 Improvement in the proinsulin/C-peptide ratio during treatment with ipragliflozin in Japanese patients with type 2 diabetes mellitus. ipragliflozin 68-81 insulin Homo sapiens 30-39 29374293-3 2018 We examined the therapeutic effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and the progression of nephropathy in uninephrectomized type 2 diabetic mice, which exhibit not only typical diabetic symptoms, such as impaired insulin secretion, glucose intolerance, hyperglycemia, and obesity, but also overt nephropathy with decline in renal function. ipragliflozin 59-72 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 43-48 28846182-4 2018 Any of the SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin, tofogliflozin, luseogliflozin or ipragliflozin) significantly decreased SUA levels compared with control (total weighted mean difference [WMD] -37.73 mumol/L, 95% CI [-40.51, -34.95]). ipragliflozin 107-120 solute carrier family 5 member 2 Homo sapiens 11-16 29479047-1 2018 Ipragliflozin is the first SGLT2 inhibitor approved in Japan. ipragliflozin 0-13 solute carrier family 5 member 2 Homo sapiens 27-32 29479047-6 2018 One year after initiation of ipragliflozin, he lost weight (body weight (BW): 79.0 to 76.2 kg), his levels of brain natriuretic peptide (BNP) decreased (191.4 to 122.5 mg/dL), and the class of his HF improved (class III to class II). ipragliflozin 29-42 natriuretic peptide B Homo sapiens 110-135 29479047-6 2018 One year after initiation of ipragliflozin, he lost weight (body weight (BW): 79.0 to 76.2 kg), his levels of brain natriuretic peptide (BNP) decreased (191.4 to 122.5 mg/dL), and the class of his HF improved (class III to class II). ipragliflozin 29-42 natriuretic peptide B Homo sapiens 137-140 29425766-0 2018 Antidiabetic effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed diets containing different carbohydrate contents. ipragliflozin 40-53 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 24-29 29425766-2 2018 Here, we investigated whether or not dietary carbohydrate content affects the efficacy of the sodium-glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin in type 2 diabetic mice. ipragliflozin 143-156 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 126-131 29322485-1 2018 INTRODUCTION: Ipragliflozin is a novel antidiabetic drug that inhibits renal tubular sodium-glucose cotransporter-2 (SGLT2). ipragliflozin 14-27 solute carrier family 5 member 2 Homo sapiens 85-115 29322485-1 2018 INTRODUCTION: Ipragliflozin is a novel antidiabetic drug that inhibits renal tubular sodium-glucose cotransporter-2 (SGLT2). ipragliflozin 14-27 solute carrier family 5 member 2 Homo sapiens 117-122 29322485-9 2018 CONCLUSION: Ipragliflozin improved glycemic control by reducing body weight, postprandial inappropriate glucagon secretion, and the postprandial insulin requirement. ipragliflozin 12-25 insulin Homo sapiens 145-152 29507299-4 2018 High- and low-dose ipragliflozin both inhibited renal and glomerular hypertrophy, and reduced NADPH oxidase 4 expression and subsequent oxidative stress. ipragliflozin 19-32 NADPH oxidase 4 Mus musculus 94-109 29507299-6 2018 Regarding renal tissue hypoxia, a short-term ipragliflozin treatment improved oxygen tension in the kidney cortex, in which SGLT2 is predominantly expressed. ipragliflozin 45-58 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 124-129 29388470-2 2018 RESEARCH DESIGN AND METHODS: STELLA-LONG TERM is an ongoing 3-year prospective surveillance study of Japanese T2DM patients receiving ipragliflozin 50 mg once daily. ipragliflozin 134-147 developmental pluripotency associated 3 Homo sapiens 29-35 29185822-2 2018 The STELLA-LONG TERM study is an ongoing 3-year post-marketing surveillance study of ipragliflozin in type 2 diabetes (T2D) patients. ipragliflozin 85-98 developmental pluripotency associated 3 Homo sapiens 4-10 29154936-0 2018 Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution. ipragliflozin 56-69 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 40-45 29154936-3 2018 Here, we investigated the possible effects of sugar solution intake on the antidiabetic effects of sodium-glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin in type 2 diabetic mice that were fed ordinary drinking water, water + glucose solution, or water + sucrose solution. ipragliflozin 148-161 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 131-136 29154936-9 2018 Our observation that the antidiabetic and antiobesity effects of the SGLT2 inhibitor ipragliflozin were not greatly affected by sugar solution intake in type 2 diabetic mice suggests that, in a clinical setting, ipragliflozin will remain an effective treatment for type 2 diabetic patients with excessive intake of carbohydrates. ipragliflozin 85-98 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 69-74 29709913-1 2018 Ipragliflozin is a selective sodium glucose cotransporter 2 (SGLT2) inhibitor that increases urinary glucose excretion and subsequently improves hyperglycemia in patients with type 2 diabetes mellitus (T2DM). ipragliflozin 0-13 solute carrier family 5 member 2 Homo sapiens 29-59 29709913-1 2018 Ipragliflozin is a selective sodium glucose cotransporter 2 (SGLT2) inhibitor that increases urinary glucose excretion and subsequently improves hyperglycemia in patients with type 2 diabetes mellitus (T2DM). ipragliflozin 0-13 solute carrier family 5 member 2 Homo sapiens 61-66 28090231-2 2017 We investigated the efficacy of the SGLT2 inhibitor ipragliflozin on diabetic nephropathy in Japanese patients with type 2 diabetes. ipragliflozin 52-65 solute carrier family 5 member 2 Homo sapiens 36-41 28924123-0 2017 The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin. ipragliflozin 195-208 solute carrier family 5 member 2 Homo sapiens 154-184 28924123-2 2017 The administration of the sodium-glucose cotransporter 2 (SGLT2) inhibitor, ipragliflozin improved her liver dysfunction clinically and histologically. ipragliflozin 76-89 solute carrier family 5 member 2 Homo sapiens 26-56 28924123-2 2017 The administration of the sodium-glucose cotransporter 2 (SGLT2) inhibitor, ipragliflozin improved her liver dysfunction clinically and histologically. ipragliflozin 76-89 solute carrier family 5 member 2 Homo sapiens 58-63 28924123-7 2017 The SGLT2 inhibitor ipragliflozin may be useful as a specific therapeutic drug for NASH. ipragliflozin 20-33 solute carrier family 5 member 2 Homo sapiens 4-9 28506912-4 2017 While all SGLT2 inhibitors exerted comparable effects in reducing hyperglycemia, improvement of these diabetes-related diseases and complications was more potent with the two long-acting drugs (ipragliflozin and dapagliflozin) than with the four intermediate-acting four drugs (tofogliflozin, canagliflozin, empagliflozin, and luseogliflozin), albeit without statistical significance. ipragliflozin 194-207 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 10-15 28490565-6 2017 METHODS AND ANALYSIS: A prospective, multicentre, blinded-endpoint phase IV randomised controlled study will be conducted to evaluate the safety and efficacy of a 24-week treatment with either an SGLT-2 inhibitor (ipragliflozin) or metformin for reducing visceral fat and plasma glucose levels in patients with type 2 diabetes. ipragliflozin 214-227 solute carrier family 5 member 2 Homo sapiens 196-202 28928461-4 2017 Here we show that ipragliflozin, a SGLT2 inhibitor, time-dependently affects behaviour and enhances energy expenditure in normal and type 2 diabetic Goto-Kakizaki (GK) rats, using continuous glucose telemetry. ipragliflozin 18-31 solute carrier family 5 member 2 Rattus norvegicus 35-40 27242192-3 2017 We report the first case of ipragliflozin-related eczematous drug eruption and a review of the past literature on drug eruptions caused by SGLT2 inhibitors. ipragliflozin 28-41 solute carrier family 5 member 2 Homo sapiens 139-144 28090231-3 2017 METHODS: A 50 mg dose of ipragliflozin was administered for 24 weeks to 50 patients with type 2 diabetes who were concomitantly managed with diet and exercise therapy alone or antidiabetic medications other than SGLT2 inhibitors. ipragliflozin 25-38 solute carrier family 5 member 2 Homo sapiens 212-217 28090231-4 2017 RESULTS: At the end of the 24-week ipragliflozin treatment, significant decreases in mean glycated hemoglobin (HbA1c) (1.0+-1.2%) and body weight (2.7 +- 2.5 kg) were observed; in addition, median urinary albumin-to-creatinine ratio (UACR) significantly decreased from 15.5 (8.0 - 85.7) to 12.9 (7.4 - 36.3) mg/gCr. ipragliflozin 35-48 nuclear receptor subfamily 3 group C member 1 Homo sapiens 311-314 28090231-9 2017 CONCLUSIONS: Our results indicate that ipragliflozin may facilitate HbA1c control and body weight reduction. ipragliflozin 39-52 hemoglobin subunit alpha 1 Homo sapiens 68-72 27628105-6 2016 In patients without chronic kidney disease, each SGLT2 inhibitor significantly increased serum magnesium levels compared with placebo (canagliflozin: WMD 0.06 mmol/l for 100 mg and 0.09 mmol/l for 300 mg; dapagliflozin: WMD 0.1 mmol/l for 10 mg; empagliflozin: WMD 0.04 mmol/l for 10 mg and 0.07 mmol/l for 25 mg; and ipragliflozin: WMD 0.05 mmol/l for 50 mg). ipragliflozin 318-331 solute carrier family 5 member 2 Homo sapiens 49-54 28458353-0 2017 The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats. ipragliflozin 45-58 solute carrier family 5 member 2 Rattus norvegicus 4-34 28458353-4 2017 In this study, we investigated the effect of the SGLT2 inhibitor ipragliflozin on body composition in a Goto-Kakizaki (GK) rat model of non-obese T2DM. ipragliflozin 65-78 solute carrier family 5 member 2 Rattus norvegicus 49-54 28458353-9 2017 Thus, an SGLT2 inhibitor ipragliflozin was found to promote preferential loss of fat mass in a rat model of non-obese T2DM. ipragliflozin 25-38 solute carrier family 5 member 2 Rattus norvegicus 9-14 27841020-0 2017 Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes. ipragliflozin 33-46 insulin Homo sapiens 50-60 27841020-0 2017 Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes. ipragliflozin 33-46 insulin Homo sapiens 61-70 27841020-3 2017 This study was performed to clarify the influence of the SGLT2 inhibitor ipragliflozin on beta-cell function assessed from the plasma intact proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes. ipragliflozin 73-86 solute carrier family 5 member 2 Homo sapiens 57-62 27841020-3 2017 This study was performed to clarify the influence of the SGLT2 inhibitor ipragliflozin on beta-cell function assessed from the plasma intact proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes. ipragliflozin 73-86 insulin Homo sapiens 141-151 27841020-3 2017 This study was performed to clarify the influence of the SGLT2 inhibitor ipragliflozin on beta-cell function assessed from the plasma intact proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes. ipragliflozin 73-86 insulin Homo sapiens 152-161 28674356-0 2017 Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor. ipragliflozin 74-87 solute carrier family 5 member 2 Homo sapiens 92-97 28674356-1 2017 We herein present the case of a 21-year-old diabetic obese woman who developed ketoacidosis following the administration of ipragliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor. ipragliflozin 124-137 solute carrier family 5 member 2 Homo sapiens 141-171 28674356-1 2017 We herein present the case of a 21-year-old diabetic obese woman who developed ketoacidosis following the administration of ipragliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor. ipragliflozin 124-137 solute carrier family 5 member 2 Homo sapiens 173-178 27436788-1 2016 AIMS: To examine the efficacy and safety of add-on ipragliflozin in Japanese patients with type 2 diabetes in the early stage of insulin therapy. ipragliflozin 51-64 insulin Homo sapiens 129-136 27436788-11 2016 CONCLUSION: Ipragliflozin was well tolerated and effective in insulin-treated patients, especially when used with a DPP-4 inhibitor. ipragliflozin 12-25 insulin Homo sapiens 62-69 27436788-11 2016 CONCLUSION: Ipragliflozin was well tolerated and effective in insulin-treated patients, especially when used with a DPP-4 inhibitor. ipragliflozin 12-25 dipeptidyl peptidase 4 Homo sapiens 116-121 27025708-0 2016 Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats. ipragliflozin 0-13 solute carrier family 5 member 2 Rattus norvegicus 17-47 27833913-0 2016 Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse. ipragliflozin 22-35 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 55-60 27833913-2 2016 Ipragliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, offers a novel approach for the treatment of diabetes by enhancing urinary glucose excretion. ipragliflozin 0-13 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 27-57 27833913-2 2016 Ipragliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, offers a novel approach for the treatment of diabetes by enhancing urinary glucose excretion. ipragliflozin 0-13 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 59-64 27833913-12 2016 Ipragliflozin administration ameliorated impaired phosphorylation of Akt and eNOSSer1177 in the abdominal aorta and reduced reactive oxygen species generation as determined by urinary excretion of 8-OHdG in diabetic mice. ipragliflozin 0-13 thymoma viral proto-oncogene 1 Mus musculus 69-72 27833913-13 2016 Furthermore, qPCR analyses demonstrated that ipragliflozin decreased the expression of inflammatory molecules [e.g., monocyte chemoattractant protein-1 (MCP-1) vascular cell adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule (ICAM)-1] in the abdominal aorta (P < 0.05). ipragliflozin 45-58 chemokine (C-C motif) ligand 2 Mus musculus 117-151 27833913-13 2016 Furthermore, qPCR analyses demonstrated that ipragliflozin decreased the expression of inflammatory molecules [e.g., monocyte chemoattractant protein-1 (MCP-1) vascular cell adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule (ICAM)-1] in the abdominal aorta (P < 0.05). ipragliflozin 45-58 chemokine (C-C motif) ligand 2 Mus musculus 153-158 27833913-13 2016 Furthermore, qPCR analyses demonstrated that ipragliflozin decreased the expression of inflammatory molecules [e.g., monocyte chemoattractant protein-1 (MCP-1) vascular cell adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule (ICAM)-1] in the abdominal aorta (P < 0.05). ipragliflozin 45-58 vascular cell adhesion molecule 1 Mus musculus 160-193 27833913-13 2016 Furthermore, qPCR analyses demonstrated that ipragliflozin decreased the expression of inflammatory molecules [e.g., monocyte chemoattractant protein-1 (MCP-1) vascular cell adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule (ICAM)-1] in the abdominal aorta (P < 0.05). ipragliflozin 45-58 vascular cell adhesion molecule 1 Mus musculus 195-201 27833913-13 2016 Furthermore, qPCR analyses demonstrated that ipragliflozin decreased the expression of inflammatory molecules [e.g., monocyte chemoattractant protein-1 (MCP-1) vascular cell adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule (ICAM)-1] in the abdominal aorta (P < 0.05). ipragliflozin 45-58 intercellular adhesion molecule 1 Mus musculus 208-248 27327650-3 2016 We conducted an 8-week study using non-diabetic mice, which were fed ad-libitum with LCHD or a normal carbohydrate diet (NCHD) and treated with/without the SGLT-2 inhibitor, ipragliflozin. ipragliflozin 174-187 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 156-162 26891133-5 2016 The patients took SGLT-2 inhibitors (ipragliflozin) for 9 days. ipragliflozin 37-50 solute carrier family 5 member 2 Homo sapiens 18-24 27619983-5 2016 The ongoing PROTECT trial was designed to assess whether the SGLT2 inhibitors, ipragliflozin, prevented progression of carotid intima-media thickness in Japanese patients with type 2 diabetes mellitus. ipragliflozin 79-92 solute carrier family 5 member 2 Homo sapiens 61-66 28116097-0 2016 Functional imaging of pharmacological action of SGLT2 inhibitor ipragliflozin via PET imaging using 11C-MDG. ipragliflozin 64-77 solute carrier family 5 member 2 Rattus norvegicus 48-53 28116097-2 2016 The aim of this study was to noninvasively visualize the pharmacological action of a selective SGLT2 inhibitor ipragliflozin in the kidney using positron emission tomography (PET) imaging with 11C-methyl-d-glucoside (11C-MDG), an SGLT-specific radio-labeled substrate. ipragliflozin 111-124 solute carrier family 5 member 2 Rattus norvegicus 95-100 27477242-0 2016 Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study. ipragliflozin 38-51 developmental pluripotency associated 3 Homo sapiens 112-118 26450351-0 2016 Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice. ipragliflozin 56-69 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 30-35 26977813-5 2016 Here we show that an SGLT2 inhibitor ipragliflozin improves hepatic steatosis in high-fat diet-induced and leptin-deficient (ob/ob) obese mice irrespective of body weight reduction. ipragliflozin 37-50 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 21-26 27081422-1 2016 BACKGROUND: Ipragliflozin is a selective sodium glucose co-transporter 2 (SGLT2) inhibitor that blocks glucose reabsorption in the proximal tubules. ipragliflozin 12-25 solute carrier family 5 member 2 Homo sapiens 41-72 27081422-1 2016 BACKGROUND: Ipragliflozin is a selective sodium glucose co-transporter 2 (SGLT2) inhibitor that blocks glucose reabsorption in the proximal tubules. ipragliflozin 12-25 solute carrier family 5 member 2 Homo sapiens 74-79 26914659-0 2016 Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors. ipragliflozin 17-30 solute carrier family 5 member 2 Homo sapiens 34-65 26914659-0 2016 Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors. ipragliflozin 17-30 glucagon Homo sapiens 238-261 26914659-0 2016 Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors. ipragliflozin 17-30 dipeptidyl peptidase 4 Homo sapiens 274-296 26829386-0 2016 Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats. ipragliflozin 10-23 solute carrier family 5 member 2 Rattus norvegicus 28-33 26450351-2 2016 In the present study, the combinatory effects of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in high-fat diet and streptozotocin-nicotinamide-induced type 2 diabetic mice were investigated. ipragliflozin 75-88 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 49-54 26731267-0 2016 The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. ipragliflozin 30-43 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 14-19 26209767-0 2015 A quantitative LC-MS/MS method for determining ipragliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, and its application to a pharmacokinetic study in rats. ipragliflozin 47-60 solute carrier family 5 member 2 Rattus norvegicus 64-95 26549210-7 2016 Treatment with ipragliflozin, an SGLT2 inhibitor, improved HbA1c from 8.4% to 6.0% and glycated albumin from 29.4% to 17.9%. ipragliflozin 15-28 solute carrier family 5 member 2 Homo sapiens 33-38 26549210-7 2016 Treatment with ipragliflozin, an SGLT2 inhibitor, improved HbA1c from 8.4% to 6.0% and glycated albumin from 29.4% to 17.9%. ipragliflozin 15-28 hemoglobin subunit alpha 1 Homo sapiens 59-63 27803440-0 2016 Visualization of mechanism of action, and a further therapeutic potential of ipragliflozin, a selective SGLT2 inhibitor. ipragliflozin 77-90 solute carrier family 5 member 2 Homo sapiens 104-109 26209767-0 2015 A quantitative LC-MS/MS method for determining ipragliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, and its application to a pharmacokinetic study in rats. ipragliflozin 47-60 solute carrier family 5 member 2 Rattus norvegicus 97-103 26209767-1 2015 Ipragliflozin is a highly potent and selective sodium-dependent glucose co-transporter-2 (SGLT2) inhibitor, a novel class of hypoglycemic agents. ipragliflozin 0-13 solute carrier family 5 member 2 Rattus norvegicus 47-88 26209767-1 2015 Ipragliflozin is a highly potent and selective sodium-dependent glucose co-transporter-2 (SGLT2) inhibitor, a novel class of hypoglycemic agents. ipragliflozin 0-13 solute carrier family 5 member 2 Rattus norvegicus 90-95 25685284-0 2015 Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan. ipragliflozin 0-13 solute carrier family 5 member 2 Homo sapiens 23-53 25805666-4 2015 Several SGLT2 inhibitors are already available in many countries (dapagliflozin, canagliflozin, empagliflozin) and in Japan (ipragliflozin, tofogliflozin). ipragliflozin 125-138 solute carrier family 5 member 2 Homo sapiens 8-13 25701721-0 2015 Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. ipragliflozin 0-13 solute carrier family 5 member 2 Rattus norvegicus 18-23 25701721-1 2015 Ipragliflozin is a selective sodium glucose cotransporter 2 (SGLT2) inhibitor that increases urinary glucose excretion by inhibiting renal glucose reabsorption and thereby causes a subsequent antihyperglycemic effect. ipragliflozin 0-13 solute carrier family 5 member 2 Rattus norvegicus 29-59 25701721-1 2015 Ipragliflozin is a selective sodium glucose cotransporter 2 (SGLT2) inhibitor that increases urinary glucose excretion by inhibiting renal glucose reabsorption and thereby causes a subsequent antihyperglycemic effect. ipragliflozin 0-13 solute carrier family 5 member 2 Rattus norvegicus 61-66 24919820-4 2015 HbA1c decreased significantly in the ipragliflozin group (-0.87%; adjusted mean difference from placebo: -1.30%; p < 0.001). ipragliflozin 37-50 hemoglobin subunit alpha 1 Homo sapiens 0-4 25685284-4 2015 Ipragliflozin is highly selective for SGLT2. ipragliflozin 0-13 solute carrier family 5 member 2 Homo sapiens 38-43 25685284-7 2015 Ipragliflozin (highly selective SGLT2 inhibitor) improves glycemic control and reduces body weight and lowers hypoglycemic risk and abdominal symptoms. ipragliflozin 0-13 solute carrier family 5 member 2 Homo sapiens 32-37 25328035-0 2015 Ameliorated pancreatic beta cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin. ipragliflozin 129-142 solute carrier family 5 member 2 Homo sapiens 88-118 25311502-8 2015 In conclusion, inhibition of sodium-glucose cotransporter 2 by ipragliflozin, alone or in combination with existing oral antidiabetic drugs, has a robust effect on blood glucose levels in a range of mouse models of hyperglycemia. ipragliflozin 63-76 solute carrier family 5 member 2 Homo sapiens 29-59 25311502-3 2015 Here, we investigated the antihyperglycemic effect of ipragliflozin, a selective sodium-glucose cotransporter 2 inhibitor, alone or in combination with oral antidiabetic drugs in a range of relevant mouse models to analyse the blood glucose-lowering properties of different drug types based on their mechanism of action. ipragliflozin 54-67 solute carrier family 5 member 2 Homo sapiens 81-111 25328035-2 2015 The current pilot study investigated beta cell function after a four-week treatment with a sodium-glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. ipragliflozin 140-153 solute carrier family 5 member 2 Homo sapiens 91-121 25328035-2 2015 The current pilot study investigated beta cell function after a four-week treatment with a sodium-glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. ipragliflozin 140-153 solute carrier family 5 member 2 Homo sapiens 123-128 25352807-7 2014 The model shows that concentration levels of tofogliflozin, ipragliflozin, and empagliflozin are higher than levels of other inhibitors following administration of marketed SGLT2 inhibitors at labeled doses and non-marketed SGLT2 inhibitors at maximal doses (approved for phase 2/3 studies). ipragliflozin 60-73 solute carrier family 5 member 2 Homo sapiens 173-178 25515334-2 2014 We therefore hypothesized that patients with hypertension treated with an angiotensin II receptor blocker (candesartan) would probably have an increased response to sodium-dependent glucose cotransporter inhibitor therapy (ipragliflozin) compared with patients treated with alternative hypertensive medications such as calcium channel blockers (nifedipine). ipragliflozin 223-236 solute carrier family 5 member 11 Homo sapiens 165-203 25515334-3 2014 Although sodium-dependent glucose cotransporter inhibitor (ipragliflozin) is a new anti-diabetic medicine, the clinical efficacy in the Japanese population has not been fully evaluated. ipragliflozin 59-72 solute carrier family 5 member 11 Homo sapiens 9-47 25316572-0 2014 Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin. ipragliflozin 76-89 solute carrier family 5 member 2 Homo sapiens 60-65 25316572-1 2014 Ipragliflozin (Suglat( )) is a potent and selective inhibitor of sodium-glucose cotransporter-2 that was recently launched in Japan. ipragliflozin 0-13 solute carrier family 5 member 2 Homo sapiens 65-95 26366172-7 2015 Administration of ipragliflozin, a selective inhibitor of sodium-glucose cotransporter 2, in the mouse model of repetitive glucose spikes inhibited the progression of atherosclerosis, whereas long-term repetitive glucose spikes, repetitive hypoglycaemia, and their combination had no significant impact on atherosclerosis. ipragliflozin 18-31 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 58-88 25149596-1 2014 AIMS: Ipragliflozin is a novel and highly selective sodium-glucose transporter 2 (SGLT2) inhibitor that reduces plasma glucose levels by enhancing urinary glucose excretion in patients with type 2 diabetes mellitus (T2DM). ipragliflozin 6-19 solute carrier family 5 member 2 Homo sapiens 52-80 25149596-1 2014 AIMS: Ipragliflozin is a novel and highly selective sodium-glucose transporter 2 (SGLT2) inhibitor that reduces plasma glucose levels by enhancing urinary glucose excretion in patients with type 2 diabetes mellitus (T2DM). ipragliflozin 6-19 solute carrier family 5 member 2 Homo sapiens 82-87 23707905-2 2013 In the present study, the therapeutic effects of SGLT2 selective inhibitor ipragliflozin were examined in high-fat diet and streptozotocin-nicotinamide-induced type 2 diabetic mice which exhibit impaired insulin secretion, insulin resistance, hyperlipidemia, hepatic steatosis, and obesity. ipragliflozin 75-88 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 49-54 24668021-1 2014 Ipragliflozin (Suglat [Japan]), an orally active, next-generation sodium-glucose transporter 2 (SGLT2) inhibitor, has been developed by Astellas Pharma and Kotobuki Pharmaceutical for the treatment of type 2 diabetes mellitus. ipragliflozin 0-13 solute carrier family 5 member 2 Homo sapiens 67-95 24668021-1 2014 Ipragliflozin (Suglat [Japan]), an orally active, next-generation sodium-glucose transporter 2 (SGLT2) inhibitor, has been developed by Astellas Pharma and Kotobuki Pharmaceutical for the treatment of type 2 diabetes mellitus. ipragliflozin 0-13 solute carrier family 5 member 2 Homo sapiens 97-102 24668021-2 2014 Ipragliflozin has received its first global approval in this indication in Japan, for use as monotherapy or in combination with another antihyperglycaemic agent (metformin, pioglitazone, a sulfonylurea, an alpha-glucosidase inhibitor, a dipeptidylpeptidase-4 inhibitor or nateglinide). ipragliflozin 0-13 dipeptidyl peptidase 4 Homo sapiens 237-258 24533859-2 2014 Here, we investigated the therapeutic effects of SGLT2 selective inhibitor ipragliflozin in type 1 diabetic rats. ipragliflozin 75-88 solute carrier family 5 member 2 Rattus norvegicus 49-54 24533859-9 2014 CONCLUSION: These results suggest that SGLT2 selective inhibitor ipragliflozin exerts a beneficial effect on glycaemic control and ameliorates diabetes-associated metabolic abnormalities and complications in STZ-induced diabetic rats, and would be a potential agent for the treatment of type 1 diabetes. ipragliflozin 65-78 solute carrier family 5 member 2 Rattus norvegicus 39-44 24668021-3 2014 Ipragliflozin is the first SGLT2 inhibitor to be approved in Japan. ipragliflozin 0-13 solute carrier family 5 member 2 Homo sapiens 27-32 24486393-0 2014 SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. ipragliflozin 26-39 solute carrier family 5 member 2 Rattus norvegicus 0-5 24486393-1 2014 Ipragliflozin is a novel and selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that induces sustained increases in urinary glucose excretion by inhibiting renal glucose reabsorption and thereby exerting a subsequent antihyperglycemic effect. ipragliflozin 0-13 solute carrier family 5 member 2 Rattus norvegicus 39-69 24486393-1 2014 Ipragliflozin is a novel and selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that induces sustained increases in urinary glucose excretion by inhibiting renal glucose reabsorption and thereby exerting a subsequent antihyperglycemic effect. ipragliflozin 0-13 solute carrier family 5 member 2 Rattus norvegicus 71-76 23707905-5 2013 In addition, ipragliflozin reduced plasma and liver levels of oxidative stress biomarkers (thiobarbituric acid reactive substances and protein carbonyl) and inflammatory markers (interleukin 6, tumor necrosis factor alpha, monocyte chemotactic protein-1, and c-reactive protein), and improved liver injury as assessed by plasma levels of aminotransferases. ipragliflozin 13-26 interleukin 6 Mus musculus 179-221 23707905-5 2013 In addition, ipragliflozin reduced plasma and liver levels of oxidative stress biomarkers (thiobarbituric acid reactive substances and protein carbonyl) and inflammatory markers (interleukin 6, tumor necrosis factor alpha, monocyte chemotactic protein-1, and c-reactive protein), and improved liver injury as assessed by plasma levels of aminotransferases. ipragliflozin 13-26 chemokine (C-C motif) ligand 2 Mus musculus 223-253 23707905-5 2013 In addition, ipragliflozin reduced plasma and liver levels of oxidative stress biomarkers (thiobarbituric acid reactive substances and protein carbonyl) and inflammatory markers (interleukin 6, tumor necrosis factor alpha, monocyte chemotactic protein-1, and c-reactive protein), and improved liver injury as assessed by plasma levels of aminotransferases. ipragliflozin 13-26 C-reactive protein, pentraxin-related Mus musculus 259-277 23707905-6 2013 These results demonstrate that SGLT2 selective inhibitor ipragliflozin improves not only hyperglycemia but also diabetes/obesity-associated metabolic abnormalities in type 2 diabetic mice and suggest that ipragliflozin may be useful in treating type 2 diabetes with metabolic syndrome. ipragliflozin 57-70 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 31-36 23707905-6 2013 These results demonstrate that SGLT2 selective inhibitor ipragliflozin improves not only hyperglycemia but also diabetes/obesity-associated metabolic abnormalities in type 2 diabetic mice and suggest that ipragliflozin may be useful in treating type 2 diabetes with metabolic syndrome. ipragliflozin 205-218 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 31-36 23910665-1 2013 BACKGROUND: Ipragliflozin, a potent, selective sodium glucose cotransporter 2 inhibitor, is in development for the treatment of type 2 diabetes mellitus. ipragliflozin 12-25 solute carrier family 5 member 2 Homo sapiens 47-77 22795925-1 2012 BACKGROUND: Ipragliflozin (ASP1941) is a selective sodium glucose cotransporter 2 inhibitor in clinical development for the treatment of patients with type 2 diabetes mellitus (T2DM). ipragliflozin 12-25 solute carrier family 5 member 2 Homo sapiens 51-81 23733389-0 2013 The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor. ipragliflozin 69-82 solute carrier family 5 member 2 Homo sapiens 92-123 23733389-0 2013 The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor. ipragliflozin 69-82 solute carrier family 5 member 2 Homo sapiens 125-130 23733389-1 2013 BACKGROUND: Ipragliflozin (ASP1941), a potent selective sodium glucose co-transporter 2 inhibitor, is in development for the treatment of type 2 diabetes mellitus. ipragliflozin 12-25 solute carrier family 5 member 2 Homo sapiens 56-87 23733389-1 2013 BACKGROUND: Ipragliflozin (ASP1941), a potent selective sodium glucose co-transporter 2 inhibitor, is in development for the treatment of type 2 diabetes mellitus. ipragliflozin 27-34 solute carrier family 5 member 2 Homo sapiens 56-87 23359360-1 2013 OBJECTIVE: Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, stimulates glycosuria and lowers glycemia in patients with type 2 diabetes (T2DM). ipragliflozin 11-24 solute carrier family 5 member 2 Homo sapiens 28-58 23276620-5 2013 RESULTS: Ipragliflozin showed a dose-dependent decrease in HbA1c of -0.49% to -0.81% at Week 12 compared with placebo (P<0.001); a decrease of -0.72% was seen with metformin. ipragliflozin 9-22 hemoglobin subunit alpha 1 Homo sapiens 59-63 23563279-0 2013 Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. ipragliflozin 0-13 solute carrier family 5 member 2 Homo sapiens 56-61 23563279-3 2013 Ipragliflozin is an SGLT2 inhibitor in Phase 3 clinical development for the treatment of type 2 diabetes mellitus (T2DM). ipragliflozin 0-13 solute carrier family 5 member 2 Homo sapiens 20-25 23163880-1 2013 AIMS: Ipragliflozin is a novel, selective inhibitor of sodium glucose co-transporter 2 (SGLT2 inhibitor) in clinical development for type 2 diabetes mellitus (T2DM) treatment. ipragliflozin 6-19 solute carrier family 5 member 2 Homo sapiens 88-93 22795925-1 2012 BACKGROUND: Ipragliflozin (ASP1941) is a selective sodium glucose cotransporter 2 inhibitor in clinical development for the treatment of patients with type 2 diabetes mellitus (T2DM). ipragliflozin 27-34 solute carrier family 5 member 2 Homo sapiens 51-81 29790389-2 2018 Here we first compared the effect of the SGLT2 inhibitor ipragliflozin (Ipra, 0.01% in diet for 8 wk) and vehicle (Veh) in Spontaneously Diabetic Torii rat, a nonobese type 2 diabetic model, and nondiabetic Sprague-Dawley rats. ipragliflozin 57-70 solute carrier family 5 member 2 Rattus norvegicus 41-46 22139434-0 2012 Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. ipragliflozin 27-40 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 70-75 22139434-0 2012 Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. ipragliflozin 42-49 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 70-75 22139434-2 2012 In vitro, the potency of ipragliflozin to inhibit SGLT2 and SGLT1 and stability were assessed. ipragliflozin 25-38 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 50-55 22139434-2 2012 In vitro, the potency of ipragliflozin to inhibit SGLT2 and SGLT1 and stability were assessed. ipragliflozin 25-38 solute carrier family 5 (sodium/glucose cotransporter), member 1 Mus musculus 60-65 22139434-4 2012 Ipragliflozin potently and selectively inhibited human, rat, and mouse SGLT2 at nanomolar ranges and exhibited stability against intestinal glucosidases. ipragliflozin 0-13 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 71-76 22139434-9 2012 These results suggest that ipragliflozin is an orally active SGLT2 selective inhibitor that induces sustained increases in urinary glucose excretion by inhibiting renal glucose reabsorption, with subsequent antihyperglycemic effect and a low risk of hypoglycemia. ipragliflozin 27-40 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 61-66 22971845-0 2012 Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice. ipragliflozin 50-63 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 24-29 22971845-2 2012 The present study investigated the antidiabetic effects of ipragliflozin, a SGLT2-selective inhibitor, in streptozotocin-nicotinamide-induced mildly diabetic mice, which exhibited a mild decline in glucose tolerance associated with the loss of early-phase insulin secretion. ipragliflozin 59-72 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 76-81 22971845-5 2012 These results suggest that the SGLT2-selective inhibitor ipragliflozin increases urinary glucose excretion by inhibiting renal glucose reabsorption, improves hyperglycemia in streptozotocin-nicotinamide-induced mildly diabetic mice, and may be useful for treating type 2 diabetes. ipragliflozin 57-70 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 31-36 21854192-0 2011 Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. ipragliflozin 57-70 solute carrier family 5 member 2 Homo sapiens 117-158 21854192-0 2011 Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. ipragliflozin 72-79 solute carrier family 5 member 2 Homo sapiens 117-158 21854192-3 2011 METHODS: This Phase 2, randomized, placebo-controlled study investigated the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of the novel oral SGLT2 inhibitor ipragliflozin (ASP1941) in T2DM patients. ipragliflozin 182-195 solute carrier family 5 member 2 Homo sapiens 166-171 33237553-9 2021 After the administration of ipragliflozin, reductions in body weight [24.0 (2.9) vs. 23.4 (2.9) kg/m2, P = 0.002], total insulin [39.1 (12.9) vs. 34.3 (12.5) units, P = 0.013], and glycated hemoglobin [7.77 (0.97) vs. 7.40 (0.86) %, P = 0.013] were observed, without any severe side effects. ipragliflozin 28-41 insulin Homo sapiens 121-128 22507206-0 2012 Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. ipragliflozin 13-26 solute carrier family 5 member 2 Rattus norvegicus 114-145 22507206-0 2012 Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. ipragliflozin 13-26 solute carrier family 5 member 2 Rattus norvegicus 147-152 22507206-0 2012 Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. ipragliflozin 28-35 solute carrier family 5 member 2 Rattus norvegicus 114-145 22507206-0 2012 Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. ipragliflozin 28-35 solute carrier family 5 member 2 Rattus norvegicus 147-152 22507206-3 2012 Through further optimization of 14a, a novel benzothiophene derivative (14h; ipragliflozin, ASP1941) was discovered as a highly potent and selective SGLT2 inhibitor that reduced blood glucose levels in a dose-dependent manner in diabetic models KK-A(y) mice and STZ rats. ipragliflozin 77-90 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 149-154 22507206-3 2012 Through further optimization of 14a, a novel benzothiophene derivative (14h; ipragliflozin, ASP1941) was discovered as a highly potent and selective SGLT2 inhibitor that reduced blood glucose levels in a dose-dependent manner in diabetic models KK-A(y) mice and STZ rats. ipragliflozin 92-99 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 149-154 34617381-4 2022 All of the included SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin, ipragliflozin, luseogliflozin and tofogliflozin) significantly decreased SUA levels compared with those of the control (total standard mean difference (SMD) -0.965, 95% CI (-1.029, -0.901), P = 0.000, I2 = 98.7%) in patients with T2DM. ipragliflozin 84-97 solute carrier family 5 member 2 Homo sapiens 20-26 34487707-0 2021 SGLT2 inhibitor ipragliflozin exerts antihyperglycemic effects via the blood glucose-dependent increase in urinary glucose excretion in type 2 diabetic mice. ipragliflozin 16-29 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 0-5 34334532-0 2021 Efficacy and safety of adding ipragliflozin to insulin in Japanese patients with type 1 diabetes mellitus: a retrospective study. ipragliflozin 30-43 insulin Homo sapiens 47-54 34334532-3 2021 Here, we sought to assess the efficacy and safety of the sodium-glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin (IPRA) in patients with type 1 DM. ipragliflozin 106-119 solute carrier family 5 member 2 Homo sapiens 57-87 34334532-3 2021 Here, we sought to assess the efficacy and safety of the sodium-glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin (IPRA) in patients with type 1 DM. ipragliflozin 106-119 solute carrier family 5 member 2 Homo sapiens 89-94 34334532-3 2021 Here, we sought to assess the efficacy and safety of the sodium-glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin (IPRA) in patients with type 1 DM. ipragliflozin 121-125 solute carrier family 5 member 2 Homo sapiens 57-87 34334532-3 2021 Here, we sought to assess the efficacy and safety of the sodium-glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin (IPRA) in patients with type 1 DM. ipragliflozin 121-125 solute carrier family 5 member 2 Homo sapiens 89-94 34334532-7 2021 IPRA decreased HbA1c levels to 8.2 +- 1.2% (p < 0.05) and reduced insulin dose to 0.52 +- 0.17 units/kg (p < 0.01) after 24 weeks. ipragliflozin 0-4 insulin Homo sapiens 66-73 34487707-1 2021 This study investigated the antihyperglycemic effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin via the blood glucose-dependent increase in urinary glucose excretion in KK/Ay type 2 diabetic mice. ipragliflozin 110-123 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 61-91 34487707-1 2021 This study investigated the antihyperglycemic effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin via the blood glucose-dependent increase in urinary glucose excretion in KK/Ay type 2 diabetic mice. ipragliflozin 110-123 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 93-98 34279807-0 2021 Correction to: Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study. ipragliflozin 43-56 developmental pluripotency associated 3 Homo sapiens 119-125 34494293-0 2022 SGLT2 inhibitor ipragliflozin poses a low risk of hypoglycemia owing to its blood glucose-dependent urinary glucose excretion mechanism in mice. ipragliflozin 16-29 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 0-5 34494293-2 2022 This study examined the effects of the SGLT2 inhibitor ipragliflozin on blood glucose-dependent urinary glucose excretion in mice. ipragliflozin 55-68 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 39-44 34298949-6 2021 In conditioned medium made from PRAT (PRAT-CM) of Ipra-treated mice, the concentration of leptin was significantly lower than PRAT-CM of mice without Ipra treatment. ipragliflozin 50-54 leptin Mus musculus 90-96 34298949-2 2021 We determined whether changes in perirenal fat (PRAT) by a SGLT2 inhibitor ipragliflozin (Ipra) contribute to the suppression of DN development. ipragliflozin 75-88 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 59-64 34298949-10 2021 In vitro experiments suggest that reduced PRAT-derived leptin by Ipra could inhibit GECs proliferation, possibly contributing to the suppression of DN development. ipragliflozin 65-69 leptin Mus musculus 55-61 34298949-2 2021 We determined whether changes in perirenal fat (PRAT) by a SGLT2 inhibitor ipragliflozin (Ipra) contribute to the suppression of DN development. ipragliflozin 90-94 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 59-64 35285452-6 2022 The protein expression levels of Na+/H+ exchanger isoform 3 (NHE3) and Na+-K+-Cl- cotransporter 2 (NKCC2) in the kidney were significantly decreased with losartan monotherapy and combination treatment, but not with ipragliflozin monotherapy. ipragliflozin 215-228 solute carrier family 9 member A3 Rattus norvegicus 61-65 34567919-5 2021 Change in leptin positively correlated with insulin, while change in total ketone bodies inversely correlated with ALT in ipragliflozin using groups. ipragliflozin 122-135 leptin Homo sapiens 10-16 34285473-0 2021 Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date. ipragliflozin 11-24 solute carrier family 5 member 2 Homo sapiens 34-40 34285473-2 2021 Ipragliflozin is a potent, selective SGLT-2 inhibitor used for the management of type 2 diabetes. ipragliflozin 0-13 solute carrier family 5 member 2 Homo sapiens 37-43 34567926-1 2021 Background: STELLA-LONG TERM was a 3-year post-marketing surveillance study that evaluated the long-term safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus (T2DM). ipragliflozin 133-146 developmental pluripotency associated 3 Homo sapiens 12-18 35285452-6 2022 The protein expression levels of Na+/H+ exchanger isoform 3 (NHE3) and Na+-K+-Cl- cotransporter 2 (NKCC2) in the kidney were significantly decreased with losartan monotherapy and combination treatment, but not with ipragliflozin monotherapy. ipragliflozin 215-228 solute carrier family 12 member 1 Rattus norvegicus 99-104 35192632-2 2022 The sodium glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin was developed as a new oral hypoglycemic drug, which can improve NASH via an insulin-independent glucose-lowering effect by inhibiting glucose reabsorption in the renal proximal tubules. ipragliflozin 53-66 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 4-34 35192632-2 2022 The sodium glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin was developed as a new oral hypoglycemic drug, which can improve NASH via an insulin-independent glucose-lowering effect by inhibiting glucose reabsorption in the renal proximal tubules. ipragliflozin 53-66 solute carrier family 5 (sodium/glucose cotransporter), member 2 Mus musculus 36-41 35115614-0 2022 The sodium-glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes. ipragliflozin 45-58 solute carrier family 5 member 2 Homo sapiens 4-34 35115614-0 2022 The sodium-glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes. ipragliflozin 45-58 insulin Homo sapiens 87-94